Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

Hui Zhang, Yong Wang, Huaguo Wu, Shizhen Zhou, Shuo Li, Xiangji Meng, Rongjie Tao, Jinming YuFrontiers in Oncology 2022 · DOI

TL;DR

This paper presents a case study of a non-small cell lung cancer (NSCLC) patient with brain and leptomeningeal metastases who developed resistance to osimertinib. The researchers successfully treated this patient with a combination of olaparib (a PARP inhibitor) and dacomitinib (a second-generation EGFR TKI), achieving a progression-free survival of 6 months and an overall survival of 13 months. This represents the first reported instance of using this specific drug combination for leptomeningeal metastases post-osimertinib resistance, offering a potential new avenue for treatment.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) patients with brain and leptomeningeal metastases face a grim prognosis, with survival often less than a year. For those with EGFR mutations, osimertinib is a standard first-line treatment, showing good intracranial activity. However, resistance to osimertinib is a significant challenge, and current follow-up treatments have limited efficacy. This paper addresses the critical unmet need for effective treatment strategies for NSCLC patients who develop brain and leptomeningeal metastases and subsequently become resistant to osimertinib.

Methods

This study is a case report combined with a systematic review of existing literature. The core of the paper details the treatment of a single patient. The key methodological innovation lies in the therapeutic approach:

  • Combination Therapy: The patient was treated with olaparib (a Poly (ADP-ribose) polymerase (PARP) inhibitor) in combination with dacomitinib (a second-generation EGFR tyrosine kinase inhibitor (TKI)).
  • Personalized Treatment: The treatment regimen was guided by genetic testing of cerebrospinal fluid (CSF), which identified specific mutations (EGFR p.L858R, TP53, and ERBB2) that were not detected in plasma.
  • Systematic Review: The authors contextualize their findings by reviewing existing literature on NSCLC brain metastases, osimertinib resistance mechanisms, and potential therapeutic strategies.

Datasets

Not discussed in the paper. The study focuses on a single patient's clinical data and genetic testing results.

Key Insights and Ideas

  • CSF Genetic Testing is Crucial: The case highlights the critical importance of cerebrospinal fluid (CSF) genetic testing. In this patient, plasma genetic testing was negative for EGFR mutations, but CSF testing revealed key mutations (EGFR p.L858R, TP53, and ERBB2) that were instrumental in guiding the successful treatment strategy. This underscores that CSF cfDNA can provide a more accurate picture of CNS metastases' genetic landscape.
  • Olaparib + Dacomitinib Synergy: The combination of olaparib and dacomitinib demonstrated efficacy in a patient resistant to osimertinib, suggesting a potential synergistic effect. This is particularly interesting given the presence of ERBB2 and TP53 mutations, which may be targeted by this combination.
  • ERBB2 and TP53 Mutations as Predictors: The presence of ERBB2 and TP53 mutations in the CSF was a key factor in selecting the treatment. This suggests these mutations might be important indicators for response to PARP inhibitors and second-generation EGFR TKIs in the context of osimertinib resistance.
  • Overcoming Blood-Brain Barrier Challenges: While osimertinib has improved blood-brain barrier penetration compared to earlier TKIs, resistance remains an issue. The combination therapy's success suggests it may offer a way to overcome resistance and effectively treat CNS metastases.

Key Results

  • Progression-Free Survival (PFS): The patient achieved 6 months of PFS after the diagnosis of leptomeningeal metastasis.
  • Overall Survival (OS): The patient achieved 13 months of OS after the diagnosis of leptomeningeal metastasis. This is considered a significant improvement over the typical median survival of less than one year for this patient population.
  • Symptom Improvement: The patient experienced significant improvement in symptoms like headache and dizziness, along with an improved quality of life after the treatment switch.
  • Genetic Findings: CSF genetic testing revealed EGFR p.L858R, TP53 p.R273C, and ERBB2 p.S442L mutations, guiding the treatment.

Limitations and Future Work

  • Single Case Study: The primary limitation is that this is a case report based on a single patient. The findings cannot be generalized without larger clinical trials.
  • Complex Regimen: The patient received a combination of multiple drugs (olaparib, dacomitinib, anlotinib, pemetrexed, and temozolomide), making it difficult to isolate the exact contribution of each agent.
  • Future Directions: The authors emphasize the need for further research into combination therapies for osimertinib-resistant NSCLC with CNS metastases. They suggest that PARP inhibitors, in combination with EGFR-TKIs, hold promise and warrant further investigation in clinical trials. The role of CSF genetic testing in guiding personalized treatment for these patients is also highlighted as a crucial area for future focus.

Summary updated

Abstract

Lung cancer patients with brain and leptomeningeal metastases usually have poor prognosis. For those patients with EGFR mutations, osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the first choice of treatment. However, drug resistance to osimertinib frequently occurs; and to date, the available follow-up treatment strategies have limited efficacy. In this case study, we report that treatments with olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, combined with dacomitinib, a second-generation EGFR TKI, benefited a lung cancer patient with osimertinib-resistant brain and leptomeningeal metastases. This 55-year-old male patient was found to have a pL858R mutation on EGFR exon 21 combined with TP53 and ERBB2 mutations after developing drug resistance to osimertinib treatment. Based on the genetic testing results, he was treated with olaparib and dacomitinib, and obtained 6 months of progression-free survival (PFS) and 13 months of overall survival (OS) after the diagnosis of leptomeningeal metastasis. This case report represents the first study applying PARP inhibitor in combination with dacomitinib in the treatment of leptomeningeal metastases after osimertinib resistance.
BibTeX
@inproceedings{zhang2022olaparib,
  author = {Hui Zhang and Yong Wang and Huaguo Wu and Shizhen Zhou and Shuo Li and Xiangji Meng and Rongjie Tao and Jinming Yu},
  title = {{Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.877279},
}
Figure